These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 25381142)

  • 41. [Relation of non-alcoholic hepatic steatosis to early carotid atherosclerosis in diet-controlled impaired glucose tolerance subjects].
    Pagano AB; Vecchio C; Giangreco E; Neri S
    Clin Ter; 2012; 163(3):205-10. PubMed ID: 22964692
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonalcoholic fatty liver disease and cardiovascular risk: is there a place for obstructive sleep apnea?
    Mirrakhimov AE; Mirrakhimov EM
    Can J Cardiol; 2013 Sep; 29(9):1139.e7. PubMed ID: 23265092
    [No Abstract]   [Full Text] [Related]  

  • 43. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study.
    Vlachopoulos C; Manesis E; Baou K; Papatheodoridis G; Koskinas J; Tiniakos D; Aznaouridis K; Archimandritis A; Stefanadis C
    Am J Hypertens; 2010 Nov; 23(11):1183-9. PubMed ID: 20634799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fatty liver and the metabolic syndrome.
    Neuschwander-Tetri BA
    Curr Opin Gastroenterol; 2007 Mar; 23(2):193-8. PubMed ID: 17268250
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.
    Targher G; Bertolini L; Padovani R; Rodella S; Tessari R; Zenari L; Day C; Arcaro G
    Diabetes Care; 2007 May; 30(5):1212-8. PubMed ID: 17277038
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reply to Mirrakhimov and Mirrakhimov--nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents.
    Alp H
    Can J Cardiol; 2013 Sep; 29(9):1139.e9. PubMed ID: 23352427
    [No Abstract]   [Full Text] [Related]  

  • 47. Carotid atherosclerosis or nonalcoholic fatty liver disease: which comes first?
    Dogru T; Genc H; Ercin CN
    Atherosclerosis; 2013 Dec; 231(2):187-8. PubMed ID: 24267223
    [No Abstract]   [Full Text] [Related]  

  • 48. Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease.
    Rowe IA; Allen AM
    Hepatology; 2023 Jun; 77(6):1843-1845. PubMed ID: 36738088
    [No Abstract]   [Full Text] [Related]  

  • 49. The epidemiology of fatty liver.
    Bellentani S; Bedogni G; Miglioli L; Tiribelli C
    Eur J Gastroenterol Hepatol; 2004 Nov; 16(11):1087-93. PubMed ID: 15489565
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular phenotype of nonalcoholic fatty liver disease: hanging the paradigm about the role of distant toxic fat accumulation on vascular disease.
    Sookoian S; Castaño GO; Pirola CJ
    Hepatology; 2012 Sep; 56(3):1185-6. PubMed ID: 22505369
    [No Abstract]   [Full Text] [Related]  

  • 51. Nonalcoholic fatty liver disease in developing countries.
    Bahrami H
    World J Gastroenterol; 2005 Jun; 11(24):3808-9. PubMed ID: 15968747
    [No Abstract]   [Full Text] [Related]  

  • 52. Ageing, inflammation, and oxidative stress: final common pathways of cardiovascular disease.
    Lüscher TF
    Eur Heart J; 2015 Dec; 36(48):3381-3. PubMed ID: 26690751
    [No Abstract]   [Full Text] [Related]  

  • 53. Oxidative stress and inflammation: new molecular targets for cardiovascular diseases.
    Becatti M; Mannucci A; Taddei N; Fiorillo C
    Intern Emerg Med; 2018 Aug; 13(5):647-649. PubMed ID: 29858969
    [No Abstract]   [Full Text] [Related]  

  • 54. Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease.
    Song C; Long X; He J; Huang Y
    Front Pharmacol; 2023; 14():1081334. PubMed ID: 37007030
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunological mechanisms and therapeutic targets of fatty liver diseases.
    Wang H; Mehal W; Nagy LE; Rotman Y
    Cell Mol Immunol; 2021 Jan; 18(1):73-91. PubMed ID: 33268887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases.
    Zhao P; Saltiel AR
    J Biol Chem; 2020 Aug; 295(34):12279-12289. PubMed ID: 32651233
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity.
    Kim SH; Park HY; Lee HS; Jung KS; Lee MH; Jhee JH; Kim TH; Lee JE; Kim HJ; Kim BS; Park HC; Lee BK; Choi HY
    Sci Rep; 2020 Jan; 10(1):1025. PubMed ID: 31974458
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonalcoholic Fatty Liver Disease, Cardiovascular Risk, and Carotid Inflammation.
    Al-Rasadi K; Rizzo M; Montalto G; Berg G
    Angiology; 2015 Aug; 66(7):601-3. PubMed ID: 25381142
    [No Abstract]   [Full Text] [Related]  

  • 59. Perspective: nonalcoholic fatty liver disease and cardiovascular risk.
    Nestel PJ; Mensink RP
    Curr Opin Lipidol; 2013 Feb; 24(1):1-3. PubMed ID: 23298957
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nonalcoholic fatty liver disease and vascular risk.
    Bhatia LS; Curzen NP; Byrne CD
    Curr Opin Cardiol; 2012 Jul; 27(4):420-8. PubMed ID: 22596186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.